Von Willebrand Factor Collagen-Binding Activity and Von Willebrand Factor-Mediated Platelet Adhesion in Patients with

Related Experiment Video

Updated: Jun 11, 2025

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.2K

Zufar Gabbasov1, Sergey Okhota2, Yuliya Avtaeva1

  • 1Laboratory of Cell Hemostasis, Chazov National Medical Research Centre of Cardiology of the Ministry of Health of the Russian Federation, 121552 Moscow, Russia.

Biomedicines
|September 28, 2024
PubMed

Insights

Lower von Willebrand factor collagen-binding activity (VWF:CB) and altered VWF-mediated platelet adhesion are linked to coronary artery disease (CAD). These VWF-collagen-platelet interactions may play a critical role in CAD development.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Biochemistry

Background:

  • Coronary artery disease (CAD) is a significant global health concern.
  • Von Willebrand factor (VWF) plays a crucial role in hemostasis and thrombosis.
  • Understanding VWF's role in CAD pathogenesis is essential for developing new therapeutic strategies.

Purpose of the Study:

  • To investigate VWF-related parameters in patients with and without stable CAD.
  • To determine the association between VWF-collagen-platelet interactions and CAD.
  • To explore the diagnostic and prognostic value of VWF:CB and VWF-mediated platelet adhesion in CAD.

Main Methods:

  • Compared VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo), VWF collagen-binding activity (VWF:CB), and VWF-mediated platelet adhesion in 30 CAD patients and 50 controls.
  • Measured platelet adhesion using a microfluidic chamber with a collagen-coated surface at high shear rates.
  • Analyzed data adjusting for traditional cardiovascular risk factors.

Main Results:

  • VWF:Ag and VWF:RCo levels were similar between CAD patients and controls.
  • VWF:CB was significantly lower in CAD patients compared to controls (106.7% vs. 160.4%, p < 0.001).
  • GPIb-mediated platelet adhesion showed a more pronounced decrease after inhibition in CAD patients (76.0% vs. 29.3%, p < 0.001).
  • Increased VWF:CB and decreased GPIb-mediated platelet adhesion were independently associated with CAD risk.

Conclusions:

  • VWF:CB and VWF-mediated platelet adhesion are altered in patients with CAD.
  • Complex VWF-collagen-platelet interactions may critically contribute to the development of CAD.
  • These VWF parameters hold potential as biomarkers for CAD risk stratification.

Keywords:
collagencoronary artery diseaseglycoprotein Ibplatelet adhesionvon Willebrand factor

More Related Videos

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions10:24

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions

Published on: June 11, 2015

10.6K
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

11.6K

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.1K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
3
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
636
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483